

Name: _____ Address: _____ Phone: _____
 SSN: _____ DOB: _____ Sex: _____
 Weight: _____ Height: _____ Allergies: _____ Ship to: Patient Clinic

Prescription Card: _____ Name of Insurer: _____ ID# _____ BIN: _____ PCN: _____
 Group: _____ (please attach copies of insurance cards)

L40.0 Psoriasis L40.5 Psoriatic Arthritis L40.59 Psoriasis Arthropathy L40.9 Psoriasis, Unspecified L73.2 Hidradenitis Suppurativa
 ICD-10: _____ Diagnosis: _____ Has TB test been done? Yes No Date: _____
 Test Result: _____ Does the patient have an active infection? Yes No
 HBV ? Yes No if yes, is pt being treated? Yes No BSA% affected _____ Location of Psoriasis _____
 Prior Failed Therapy? _____ Start Date: _____ End Date: _____
 Reason for DC: _____ Current Medications: _____

Medication	Dose	Directions	Quantity	Refill
<input type="checkbox"/> Cimzia (Certolizumab)	<input type="checkbox"/> 200 mg/ml PFS	<input type="checkbox"/> Initial: inject 400 mg SC at 0, 2 and 4 weeks	<input type="checkbox"/> 6 x 200 mg/ml	0
	<input type="checkbox"/> 200 mg vials	Maintenance: <input type="checkbox"/> Inject 200 mg SC every 2 weeks <input type="checkbox"/> Inject 400 mg SC every 4 weeks <input type="checkbox"/> Other _____	<input type="checkbox"/> 2 x 200 mg/ml	_____
<input type="checkbox"/> Enbrel (Etanercept)	<input type="checkbox"/> 50 mg/ml auto-injector	<input type="checkbox"/> Initial: inject 50 mg SC twice wkl for 3 months	<input type="checkbox"/> 8 x 50 mg/ml	2
	<input type="checkbox"/> 50 mg/ml PFS	Maintenance: <input type="checkbox"/> Inject 50 mg SC once weekly	<input type="checkbox"/> 4 x 50 mg/ml	_____
<input type="checkbox"/> Humira (Adalimumab)	<input type="checkbox"/> 40 mg/0.8ml pens <input type="checkbox"/> 40 mg/0.8ml PFS	Plaque Psoriasis: <input type="checkbox"/> Initial: 80 mg SC as a single dose	<input type="checkbox"/> 2 x 40 mg/0.8ml	0
		Maintenance: <input type="checkbox"/> 40 mg SC every other week Beginning one week after initial dose	<input type="checkbox"/> 2 x 40 mg/0.8ml	_____
		Psoriatic Arthritis: <input type="checkbox"/> Inject 40 mg SC every other week	<input type="checkbox"/> 2 x 40 mg/0.8ml	_____
		Hidradenitis Suppurativa: <input type="checkbox"/> Initial: 160 mg SC on day then 80 mg 2 weeks later	<input type="checkbox"/> 6 x 40 mg/0.8ml	0
		Maintenance: <input type="checkbox"/> 40 mg SC every week, starting on day 29 <input type="checkbox"/> Other _____	<input type="checkbox"/> 4 x 40 mg/0.8ml	_____
<input type="checkbox"/> Otezla (Apremilast)	<input type="checkbox"/> Starter pack	<input type="checkbox"/> Follow package insert directions	<input type="checkbox"/> 1 pack (55 tablets)	0
	<input type="checkbox"/> 30 mg tab	Maintenance: <input type="checkbox"/> Take 30 mg by mouth twice daily <input type="checkbox"/> Other: _____	<input type="checkbox"/> 60 tablets	_____
<input type="checkbox"/> Simponi (Golimumab)	<input type="checkbox"/> 50 mg/0.5ml autoinjector <input type="checkbox"/> 50 mg/0.5ml PFS	<input type="checkbox"/> Inject 50 mg SC once a month	<input type="checkbox"/> 1 x 50 mg/0.5ml	_____
<input type="checkbox"/> Stelara (Ustekinumab)	<input type="checkbox"/> 45 mg/0.5ml PFS <input type="checkbox"/> 90 mg/ml PFS Dosing: <input type="checkbox"/> ≤100Kg: 45mg <input type="checkbox"/> >100Kg: 90mg	<input type="checkbox"/> Initial: inject 45 mg SC at weeks 0 and 4 <input type="checkbox"/> Or inject 90 mg SC at weeks 0 and 4	<input type="checkbox"/> 2 x 45 mg/0.5ml <input type="checkbox"/> 2 x 90 mg/ml	0
		Maintenance: <input type="checkbox"/> Inject 45 mg SC every 12 weeks <input type="checkbox"/> Inject 90 g SC every 12 weeks	<input type="checkbox"/> 1 x 45 mg/0.5ml <input type="checkbox"/> 1 x 90 mg/ml	_____
<input type="checkbox"/> Other	_____	_____	_____	_____

PRESCRIBER INFORMATION

Physician Name: _____ Address: _____
 State License#: _____ NPI: _____ DEA: _____
 Phone #: _____ Fax #: _____ Office Contact Name /Number: _____
 Prescriber's Signature: _____ Date: _____

I authorize pharmax specialty pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process.
 Confidentiality statement: this message is intended only for the individual or entity to which it is addressed. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws. If the reader of this form is not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information or copying this information. If you have received this communication in error, please notify us immediately by telephone.